{"id":28641,"date":"2025-10-22T19:12:23","date_gmt":"2025-10-22T19:12:23","guid":{"rendered":"https:\/\/www.euforea.org\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/"},"modified":"2026-08-20T09:27:30","modified_gmt":"2026-08-20T09:27:30","slug":"ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/","title":{"rendered":"Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"28641\" class=\"elementor elementor-28641 elementor-16726\" data-elementor-post-type=\"news\">\n\t\t\t\t<div class=\"elementor-element elementor-element-0406419 e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no e-con e-parent\" data-id=\"0406419\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-843a778 elementor-widget elementor-widget-euforea_general_content\" data-id=\"843a778\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"euforea_general_content.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"paragraphs\">\n    <div data-quickedit-entity-id=\"paragraph\/842\" class=\"paragraph paragraph--text-columns paragraph-id--842 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n      <div class=\"inner--wide\">\n        <div class=\"text__text text text--paragraph\">\n        \t          <p>La rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (CRSwNP) est\u00e1 impulsada predominantemente por la inflamaci\u00f3n de tipo 2 que involucra las v\u00edas de IL-4\/IL-13, IL-5 e IgE. Agentes biol\u00f3gicos como Dupilumab, Mepolizumab y Omalizumab act\u00faan sobre estos mediadores clave y han demostrado una eficacia cl\u00ednica significativa. <\/p>\n<p>Sin embargo, la evidencia comparativa directa ha sido limitada, hasta el <strong>Ensayo EVEREST<\/strong> (EValuating trEatment RESponses of dupilumab versus omalizumab), el primer estudio internacional, aleatorizado, doble ciego de fase 4 para evaluar ambos biol\u00f3gicos de forma directa en pacientes con CRSwNP grave e incontrolada, con o sin asma. Este v\u00eddeo revisa el dise\u00f1o del ensayo, los resultados y los conocimientos mecanicistas, destacando las implicaciones para la terapia de precisi\u00f3n en el manejo de la CRSwNP. <\/p>\n<p>Haga clic <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41033334\/\"><strong>aqu\u00ed<\/strong><\/a> para leer el art\u00edculo m\u00e1s reciente sobre EVEREST en PubMed.<\/p>\n<p>\u00a1Vea este episodio con nuestros invitados especiales, el <strong>Prof. Eugenio De Corso (Italia)<\/strong> y el <strong>Prof. Joaquim Mullol (Espa\u00f1a)<\/strong>, para comprender c\u00f3mo las terapias biol\u00f3gicas est\u00e1n transformando la atenci\u00f3n a los pacientes con p\u00f3lipos nasales y asma!<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-05eafb3 e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no e-con e-parent\" data-id=\"05eafb3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d307a7b elementor-widget elementor-widget-video\" data-id=\"d307a7b\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;youtube_url&quot;:&quot;https:\\\/\\\/youtu.be\\\/zGmk0o82LYQ&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}\" data-widget_type=\"video.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-wrapper elementor-open-inline\">\n\t\t\t<div class=\"elementor-video\"><\/div>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>La rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (CRSwNP) est\u00e1 impulsada predominantemente por la inflamaci\u00f3n de tipo 2 que involucra las v\u00edas de IL-4\/IL-13, IL-5 e IgE. Agentes biol\u00f3gicos como Dupilumab, Mepolizumab y Omalizumab act\u00faan sobre estos mediadores clave y han demostrado una eficacia cl\u00ednica significativa. Sin embargo, la evidencia comparativa directa ha sido limitada, hasta el Ensayo EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), el primer estudio internacional, aleatorizado, doble ciego de fase 4 para evaluar ambos biol\u00f3gicos de forma directa en pacientes con CRSwNP grave e incontrolada, con o sin asma. Este v\u00eddeo revisa el dise\u00f1o del ensayo, los resultados y los conocimientos mecanicistas, destacando las implicaciones para la terapia de precisi\u00f3n en el manejo de la CRSwNP. Haga clic aqu\u00ed para leer el art\u00edculo m\u00e1s reciente sobre EVEREST en PubMed. \u00a1Vea este episodio con nuestros invitados especiales, el Prof. Eugenio De Corso (Italia) y el Prof. Joaquim Mullol (Espa\u00f1a), para comprender c\u00f3mo las terapias biol\u00f3gicas est\u00e1n transformando la atenci\u00f3n a los pacientes con p\u00f3lipos nasales y asma!<\/p>\n","protected":false},"author":9,"featured_media":28643,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[166],"tags":[],"class_list":["post-28641","news","type-news","status-publish","has-post-thumbnail","hentry","category-programas-de-noticias-de-euforea"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP\" \/>\n<meta property=\"og:description\" content=\"La rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (CRSwNP) est\u00e1 impulsada predominantemente por la inflamaci\u00f3n de tipo 2 que involucra las v\u00edas de IL-4\/IL-13, IL-5 e IgE. Agentes biol\u00f3gicos como Dupilumab, Mepolizumab y Omalizumab act\u00faan sobre estos mediadores clave y han demostrado una eficacia cl\u00ednica significativa. Sin embargo, la evidencia comparativa directa ha sido limitada, hasta el Ensayo EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), el primer estudio internacional, aleatorizado, doble ciego de fase 4 para evaluar ambos biol\u00f3gicos de forma directa en pacientes con CRSwNP grave e incontrolada, con o sin asma. Este v\u00eddeo revisa el dise\u00f1o del ensayo, los resultados y los conocimientos mecanicistas, destacando las implicaciones para la terapia de precisi\u00f3n en el manejo de la CRSwNP. Haga clic aqu\u00ed para leer el art\u00edculo m\u00e1s reciente sobre EVEREST en PubMed. \u00a1Vea este episodio con nuestros invitados especiales, el Prof. Eugenio De Corso (Italia) y el Prof. Joaquim Mullol (Espa\u00f1a), para comprender c\u00f3mo las terapias biol\u00f3gicas est\u00e1n transformando la atenci\u00f3n a los pacientes con p\u00f3lipos nasales y asma!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T09:27:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1748\" \/>\n\t<meta property=\"og:image:height\" content=\"1015\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\\\/\",\"name\":\"Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EVEREST-Trial-_Teaser.jpg\",\"datePublished\":\"2025-10-22T19:12:23+00:00\",\"dateModified\":\"2026-08-20T09:27:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\\\/#breadcrumb\"},\"inLanguage\":\"es-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EVEREST-Trial-_Teaser.jpg\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EVEREST-Trial-_Teaser.jpg\",\"width\":1748,\"height\":1015},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/elige-tu-camino\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/","og_locale":"es_ES","og_type":"article","og_title":"Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP","og_description":"La rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (CRSwNP) est\u00e1 impulsada predominantemente por la inflamaci\u00f3n de tipo 2 que involucra las v\u00edas de IL-4\/IL-13, IL-5 e IgE. Agentes biol\u00f3gicos como Dupilumab, Mepolizumab y Omalizumab act\u00faan sobre estos mediadores clave y han demostrado una eficacia cl\u00ednica significativa. Sin embargo, la evidencia comparativa directa ha sido limitada, hasta el Ensayo EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), el primer estudio internacional, aleatorizado, doble ciego de fase 4 para evaluar ambos biol\u00f3gicos de forma directa en pacientes con CRSwNP grave e incontrolada, con o sin asma. Este v\u00eddeo revisa el dise\u00f1o del ensayo, los resultados y los conocimientos mecanicistas, destacando las implicaciones para la terapia de precisi\u00f3n en el manejo de la CRSwNP. Haga clic aqu\u00ed para leer el art\u00edculo m\u00e1s reciente sobre EVEREST en PubMed. \u00a1Vea este episodio con nuestros invitados especiales, el Prof. Eugenio De Corso (Italia) y el Prof. Joaquim Mullol (Espa\u00f1a), para comprender c\u00f3mo las terapias biol\u00f3gicas est\u00e1n transformando la atenci\u00f3n a los pacientes con p\u00f3lipos nasales y asma!","og_url":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","article_modified_time":"2026-08-20T09:27:30+00:00","og_image":[{"width":1748,"height":1015,"url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/","url":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/","name":"Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg","datePublished":"2025-10-22T19:12:23+00:00","dateModified":"2026-08-20T09:27:30+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/#breadcrumb"},"inLanguage":"es-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/"]}]},{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg","width":1748,"height":1015},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/es\/news\/ensayo-everest-la-primera-comparacion-directa-de-2-biologicos-en-crswnp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.euforea.org\/es\/elige-tu-camino\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"Ensayo EVEREST: La primera comparaci\u00f3n directa de 2 biol\u00f3gicos en CRSwNP"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-ES"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/28641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/comments?post=28641"}],"version-history":[{"count":1,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/28641\/revisions"}],"predecessor-version":[{"id":28644,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/28641\/revisions\/28644"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media\/28643"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media?parent=28641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/categories?post=28641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/tags?post=28641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}